Research programme: G protein-coupled receptor modulators - Actelion Pharmaceuticals

Drug Profile

Research programme: G protein-coupled receptor modulators - Actelion Pharmaceuticals

Alternative Names: GPCR modulators - Actelion

Latest Information Update: 27 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals was acquired by Janssen Pharmaceuticals
  • 12 Jun 2007 Discontinued - Preclinical for Cardiovascular disorders in Switzerland (unspecified route)
  • 19 Nov 2003 Axovan has been acquired by Actelion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top